Medical Microinstruments (MMI) raised $125 million in a Series D round to scale its Symani Surgical System and pursue additional microsurgery applications. The company also described exploring new treatment concepts using its robotic microsurgery platform, including an experimental approach aimed at Alzheimer’s disease. MMI said the financing will expand the footprint of Symani beyond existing use cases, supporting commercialization and potentially widening adoption in surgical settings where microsurgical precision is critical. The round underscores continued investor appetite for enabling technologies that can differentiate procedural outcomes—particularly where measurable throughput and precision can be tied to clinical workflows.